Joint Force Pharmachem Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
as on 04-12-2024
- Paid Up Capital ₹ 0.10 M
as on 04-12-2024
- Company Age 12 Year, 7 Months
- Last Filing with ROC 31 Mar 2024
- Revenue 403.50%
(FY 2021)
- Profit 181.04%
(FY 2021)
- Ebitda -58.93%
(FY 2021)
- Net Worth 131.04%
(FY 2021)
- Total Assets 102.31%
(FY 2021)
About Joint Force Pharmachem
The Company is engaged in the Business Outsourcing Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Bodh Sikri, Rajesh Gupta, Tarun Gupta, and Two other members serve as directors at the Company.
- CIN/LLPIN
U51101MH2012PTC231651
- Company No.
231651
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
30 May 2012
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Joint Force Pharmachem?
Board Members(5)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Bodh Sikri  | Director | 20-Jun-2014 | Current |
| Rajesh Gupta | Director | 01-Jun-2012 | Current |
Tarun Gupta  | Director | 30-May-2012 | Current |
| Basant Shrivastava | Director | 25-Jun-2019 | Current |
| Sarita Tarun | Director | 30-May-2012 | Current |
Financial Performance of Joint Force Pharmachem.
Joint Force Pharmachem Private Limited, for the financial year ended 2021, experienced significant growth in revenue, with a 403.5% increase. The company also saw a substantial improvement in profitability, with a 181.04% increase in profit. The company's net worth Soared by an impressive increase of 131.04%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Joint Force Pharmachem?
In 2021, Joint Force Pharmachem had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Urihk Pharmaceutical Private LimitedActive 7 years 1 monthRajesh Gupta and Tarun Gupta are mutual person
P K Pharmatech Private LimitedActive 25 years 7 monthsRajesh Gupta and Tarun Gupta are mutual person
_PRIVATE_LIMITED.webp)
Stg Pharmagenerics Private LimitedActive 7 years 11 monthsRajesh Gupta and Tarun Gupta are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Joint Force Pharmachem?
Unlock and access historical data on people associated with Joint Force Pharmachem, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Joint Force Pharmachem, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Joint Force Pharmachem's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
